Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12614001070628
Ethics application status
Approved
Date submitted
20/09/2014
Date registered
7/10/2014
Date last updated
23/10/2020
Date data sharing statement initially provided
9/07/2019
Type of registration
Retrospectively registered

Titles & IDs
Public title
The role of sensory parameters in predicting clinical outcome after lumbar discectomy
Scientific title
The role of quantitative sensory testing parameters in predicting clinical outcome in patients undergoing lumbar discectomy
Secondary ID [1] 285063 0
nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lumbar radiculopathy with radicular pain 292587 0
Condition category
Condition code
Neurological 292891 292891 0 0
Other neurological disorders
Surgery 292892 292892 0 0
Other surgery

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
The initial participant assessment will be performed in the week prior to surgery. The once-off baseline assessment will take approximately 2.5 hours.
Standardised quantitative sensory testing (QST) will be performed according to the QST protocol of German Research Network on Neuropathic pain. The protocol includes the following assessments: cold and warm detection thresholds; the number of paradoxical heat sensations during the procedure of alternating warm and cold stimuli; cold and heat pain thresholds; mechanical detection threshold; mechanical pain threshold; stimulus-response functions: mechanical pain sensitivity and dynamic mechanical allodynia; wind-up ratio; vibration detection threshold and pressure pain threshold.

QST measurements will be taken from the main pain area nominated by the patient, as required for the assessment of neuropathic pain, and the contralateral side and from the ipsilateral hand dorsum as a remote control site, plus thermal and mechanical detection thresholds will be assessed in the relevant dermatomes (L5 or S1). Testing of the full QST protocol will take approximately 30 minutes per test area. Testing of the dermatomal detection thresholds will take less than 10 minutes.

In addition the following measurements will be taken either in interview format or via questionnaires at the initial assessment before surgery:
*Duration of pain
*Pain intensity of back and leg pain
*Health care utilisation
*Bothersomeness of back and leg pain
*Confidence in recovery (‘great deal’, ‘moderate’, ‘no confidence’, ‘do not know’)
*Intake of medication
*Sleep quality (Visual Analogue Scale)
*Duration of inability to work
*Functional status (Oswestry Disability Index)
*Anxiety and Depression (Hospital Anxiety and Depression Scale)
*Pain descriptors (painDETECT)
*Fear avoidance behaviour (Tampa Scale for Kinesiophobia)
*Pain catastrophizing (Pain catastrophizing Scale)
*Health-related quality of life (Short form-36 health questionnaire)
*Risk assessment for persistent pain (Orebro Musculoskeletal Screening Questionnaire)

Participants will be observed up to 12 months after surgery. The 3 months post-surgery assessment will include the full QST protocol just in the participants' previous maximal pain area and the reassessment of detection thresholds in the relevant dermatome. The QST assessment will take approx. 40 minutes. In addition participants will have to complete questionnaires.
Intervention code [1] 289900 0
Not applicable
Comparator / control treatment
comparison of QST data to QST data of healthy control group; comparison of QST measurements in maximal pain area before and 3 months after lumbar discectomy. The healthy control group will be assessed on a single occasion for the relevant body regions to be tested. In addition to QST measurement they will complete the SF-36 questionnaire, the Hospital Anxiety and Depression Scale
and determine their sleep quality (VAS).
Control group
Uncontrolled

Outcomes
Primary outcome [1] 292768 0
Oswestry Disability Index
Timepoint [1] 292768 0
3 months and 12 months post surgery
Primary outcome [2] 293250 0
Pain intensity (NRS -11)
Timepoint [2] 293250 0
3 and 12 months post surgery
Secondary outcome [1] 309627 0
Health related quality of life (SF-36)
Timepoint [1] 309627 0
3 and 12 months post surgery
Secondary outcome [2] 310597 0
QST maximal pain area and dermatome
Timepoint [2] 310597 0
3 months post surgery
Secondary outcome [3] 310672 0
pain descriptors (painDETECT)
Timepoint [3] 310672 0
3 and 12 months post surgery
Secondary outcome [4] 310673 0
Return to work (yes/no) (any work:full time, part time or casual)
Timepoint [4] 310673 0
3 and 12 months post surgery
Secondary outcome [5] 310674 0
Patient Global Impression of Change Scale
Timepoint [5] 310674 0
3 and 12 months post surgery
Secondary outcome [6] 310675 0
Bothersomenes of back and leg pain ;
Q: how bothersome has your back/leg pain been in the last 2 weeks? Answer: not at all, slightly, moderately, very much, extremely
Timepoint [6] 310675 0
3 and 12 months post surgery
Secondary outcome [7] 310676 0
Health care utilisation ; outcome assessed by questionnaire:
Q: What treatment options have you accessed in the past 4 weeks for your pain condition? Several health professionals are given as answer, plus participant has to indicate the number of times visited. There is no data linkage to medical records,.
Timepoint [7] 310676 0
3 and 12 months post surgery
Secondary outcome [8] 310677 0
Medication intake ; assessed by questionnaire - participant has to write down name of current medication, dosage and reason for taking this medication
Timepoint [8] 310677 0
3 and 12 months post surgery

Eligibility
Key inclusion criteria
Age 18 to 65 years; symptom duration of > 3 months; clinical diagnosis of lumbar radiculopathy (defined as conduction block along a spinal nerve or nerve root, manifesting clinically with dermatomal sensory loss or myotomal weakness or reflex changes) and leg pain in L5 or S1 dermatomal distribution; demonstrable clinically relevant abnormality on imaging studies indicating nerve root compression at the relevant spinal level; person listed on the elective neurosurgery surgery waitlist for the procedure of lumbar discectomy.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
diabetes and vascular disease, thyroid disorder, other neurological or psychiatric disease; previous lumbar surgery; a history of any disorders that potentially might affect the sensation in the hand (negative control site) to be tested and an insufficient level of English to understand and fill out the questionnaires

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Case control
Timing
Prospective
Statistical methods / analysis
Sample Size: In 2013 approximately 70 lumbar discectomies were performed on patients on the elective neurosurgery list by the consultant neurosurgeon involved in this study. A sample of 70 participants is feasible for this study, considering the exclusion criteria, loss to follow up and the given time frame of the PI’s fellowship.

The Oswestry Disability Index (ODI) will be used as primary outcome measure after surgery. The scoring of ODI is between 0-100 (100 maximum disability).
10 points or 30% score improvement is the cut-off point for minimal important change. A sample size of 40 participants is required to detect 10 units pre-post surgery with a power of 80% and 5% level of significance.

For each symptomatic participant an age (+/-5 years) and gender matched healthy control (HC) subject will be recruited.

QST data will be log-transformed prior to statistical analysis except those data which are normally distributed as raw data .

To compare and illustrate particpants’ QST data profiles with the group mean of age/gender matched healthy controls particpants’ data will be z-transformed for each single parameter by using the following expression: Z-score = (Mean single proband – Mean healthy controls)/SD healthy controls . Z-values will be calculated based on additional HC group data. The total number of HC subjects to be tested has to be determined during the course of the study as reference data have to be obtained from at least 8 HC subjects for each maximal pain area nominated by the symptomatic participants and for the dermatomes and for each age decade (20-30, 30-40, 40-50, 50-65 years) as QST parameters are depending on age.

Differences of QST data between the symptomatic participant group and HC and tested body regions will be compared using a two-way analysis of covariance (ANCOVA) with tested body areas (maximal pain area, hand) as the within-subjects factor. Group (participants/controls) will be entered as between-subjects factors. Anxiety, depression and fear avoidance scores will be entered as covariates to account for potential influence of these factors on pain responses. Depending on data distribution, differences of some predictor variables (Oswestry Disability Index, HADS,Tampa Scale for Kinesiophobia , SF-36v2 'Registered Trademark' ) between patients and HC will be compared using parametric (t-Test) or non-parametric tests (Mann-Whitney-U test).

Differences in outcome measures pre- and post-surgery will be compared using repeated measures ANOVA in case of normal distribution of variables, and the Friedman’s Test for non-normal distributed data. Multivariate regression analyses will be performed to assess associations between the predictor variables, QST measures and the outcome variables.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
30/09/2014
Actual
30/09/2014
Date of last participant enrolment
Anticipated
31/12/2021
Actual
Date of last data collection
Anticipated
31/12/2021
Actual
Sample size
Target
160
Accrual to date
131
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 2785 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 8478 0
6009 - Broadway Nedlands

Funding & Sponsors
Funding source category [1] 289668 0
Charities/Societies/Foundations
Name [1] 289668 0
Raine Medical Research Foundation
Country [1] 289668 0
Australia
Funding source category [2] 290028 0
Government body
Name [2] 290028 0
Government of Western Australia, Department of Health
Country [2] 290028 0
Australia
Funding source category [3] 300450 0
Hospital
Name [3] 300450 0
Sir Charles Gairdner and Osborne Park Health Care Group Research Advisory Committee
Country [3] 300450 0
Australia
Funding source category [4] 307052 0
Charities/Societies/Foundations
Name [4] 307052 0
Charlies Foundation for Research; Sir Charles Gairdner and Osborne Park Health Care Group Research Advisory Committee
Country [4] 307052 0
Australia
Primary sponsor type
Individual
Name
Dr Brigitte Tampin
Address
Neurosurgery Spinal Clinic, Dept of Pain Management
G Block, Lower Ground Floor
Sir Charles Gairdner Hospital
Hospital Avenue
Nedlands WA 6009
Country
Australia
Secondary sponsor category [1] 288359 0
None
Name [1] 288359 0
Address [1] 288359 0
Country [1] 288359 0
Other collaborator category [1] 278065 0
University
Name [1] 278065 0
School of Physiotherapy and Exercise Science
Curtin University
Address [1] 278065 0
GPO Box 1987
Perth WA 6845
Country [1] 278065 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 291405 0
Sir Charles Gairdner Group Human Research Ethics Committee
Ethics committee address [1] 291405 0
Ethics committee country [1] 291405 0
Australia
Date submitted for ethics approval [1] 291405 0
28/04/2014
Approval date [1] 291405 0
07/08/2014
Ethics approval number [1] 291405 0
2014-041

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes
Attachments [1] 190 190 0 0
/AnzctrAttachments/366797-HREC APPROVAL 2014-041.pdf

Contacts
Principal investigator
Name 50246 0
Dr Brigitte Tampin
Address 50246 0
Sir Charles Gairdner Hospital
Neurosurgery Spinal Clinic
Department of Pain Management
G Block, Lower Ground Floor
Hospital Avenue
Nedlands WA 6009
Country 50246 0
Australia
Phone 50246 0
+61 8 6457 7964
Fax 50246 0
+61 8 6457 3481
Email 50246 0
[email protected]
Contact person for public queries
Name 50247 0
Brigitte Tampin
Address 50247 0
Sir Charles Gairdner Hospital
Neurosurgery Spinal Clinic
Department of Pain Management
G Block, Lower Ground Floor
Hospital Avenue
Nedlands WA 6009
Country 50247 0
Australia
Phone 50247 0
+61 8 6457 7964
Fax 50247 0
+61 8 6457 3481
Email 50247 0
[email protected]
Contact person for scientific queries
Name 50248 0
Brigitte Tampin
Address 50248 0
Sir Charles Gairdner Hospital
Neurosurgery Spinal Clinic
Department of Pain Management
G Block, Lower Ground Floor
Hospital Avenue
Nedlands WA 6009
Country 50248 0
Australia
Phone 50248 0
+61 8 6457 7964
Fax 50248 0
+61 8 6457 3481
Email 50248 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
No data has yet been published


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.